NEW YORK (GenomeWeb) – Sigma-Aldrich today said that its pending $17 billion acquisition by Merck KGaA has cleared US antitrust hurdles.
The waiting period under the Hart-Scott-Rodino Antitrust Improvement Act for the proposed deal expired on Monday, clearing the way for the deal in theUS. Sigma-Aldrich and Merck KGaA are awaiting regulatory approval in other countries but continue to expect the deal to be completed in mid-2015.
Sigma-Aldrich shareholders approved the acquisition earlier this month.